Insider · CIK 0001240547
Thomas S McHugh
Files at AVDL (AVADEL PHARMACEUTICALS PLC). First filing Dec 12, 2024, latest Dec 16, 2024.
In brief
Thomas S McHugh files SEC Form 4 as CFO at AVDL (AVADEL PHARMACEUTICALS PLC). Since Dec 12, 2024, Thomas S McHugh has reported 2 open-market buys worth $76k and 0 open-market sells worth $0, the latest filed on Dec 16, 2024.
A track record needs three past buys with six months of prices behind them; Thomas S McHugh has 0, so none is measured yet.
The newest scored trade: bought $24k of AVDL on Dec 13, 2024, filed Dec 16, 2024, scored 42 (moderate).
Signals
This insider’s open-market buys and sells, scored.
| Score | Company | Value | Holdings | Price context | Filed |
|---|---|---|---|---|---|
| 42Moderate | AVADEL PHARMACEUTICALS PLC | $24k 2,300 shares | +3% | - | |
| 47Moderate | AVADEL PHARMACEUTICALS PLC | $52k 5,000 shares | +6% | - |
Transactions
Every row this insider has filed, 11 in all, newest first.
| Date | Company | Transaction | Shares | Price | Value | Holdings after | Filed |
|---|---|---|---|---|---|---|---|
| Feb 12, 2026 | AVDL AVADEL PHARMACEUTICALS PLC | DDisposition to issuer Ordinary Shares | -100,400 | $21.00 | $2.1M | 0 | Feb 12, 2026 |
| Feb 12, 2026 | AVDL AVADEL PHARMACEUTICALS PLC | DDisposition to issuer Stock Option (Right to Buy)derivative | -250,000 | - | - | 0 | Feb 12, 2026 |
| Feb 12, 2026 | AVDL AVADEL PHARMACEUTICALS PLC | DDisposition to issuer Stock Option (Right to Buy)derivative | -200,000 | - | - | 0 | Feb 12, 2026 |
| Feb 12, 2026 | AVDL AVADEL PHARMACEUTICALS PLC | DDisposition to issuer Stock Option (Right to Buy)derivative | -150,000 | - | - | 0 | Feb 12, 2026 |
| Feb 12, 2026 | AVDL AVADEL PHARMACEUTICALS PLC | DDisposition to issuer Stock Option (Right to Buy)derivative | -175,000 | - | - | 0 | Feb 12, 2026 |
| Feb 12, 2026 | AVDL AVADEL PHARMACEUTICALS PLC | DDisposition to issuer Stock Option (Right to Buy)derivative | -157,500 | - | - | 0 | Feb 12, 2026 |
| Feb 12, 2026 | AVDL AVADEL PHARMACEUTICALS PLC | DDisposition to issuer Stock Option (Right to Buy)derivative | -72,000 | - | - | 0 | Feb 12, 2026 |
| Mar 5, 2025 | AVDL AVADEL PHARMACEUTICALS PLC | AGrant or award Ordinary Shares | +12,600 | $0.00 | $0 | 100,400 | Mar 7, 2025 |
| Mar 5, 2025 | AVDL AVADEL PHARMACEUTICALS PLC | AGrant or award Stock Option (Right to Buy)derivative | +72,000 | $0.00 | $0 | 72,000 | Mar 7, 2025 |
| Dec 13, 2024 | AVDL AVADEL PHARMACEUTICALS PLC | POpen-market purchase Ordinary Shares | +2,300 | $10.44 | $24k | 87,800 | Dec 16, 2024 |
| Dec 11, 2024 | AVDL AVADEL PHARMACEUTICALS PLC | POpen-market purchase Ordinary Shares | +5,000 | $10.49 | $52k | 85,500 | Dec 12, 2024 |
Questions about Thomas S McHugh
Answered from the filings on this page, as of the latest one.
Is Thomas S McHugh buying or selling?
Not in the last 12 months. Thomas S McHugh's latest open-market trade on SEC Form 4 was bought $24k of AVDL on Dec 13, 2024.
How did Thomas S McHugh's past buys perform?
Not measured yet. InsiderTell needs three past buys with six months of prices to publish a track record, and Thomas S McHugh has 0.
Where does Thomas S McHugh file Form 4?
Thomas S McHugh has filed Form 4 at AVDL (AVADEL PHARMACEUTICALS PLC) as Chief Financial Officer. A Form 4 is required of officers, directors and holders of more than 10% of a share class within two business days of a trade.
Not investment advice. Scores and forward returns are decision support built from public SEC filings and past prices; they describe what happened after comparable filings, not what will happen after this one. Do your own research and size your risk.